Background: It has been shown that increases in intraluminal flow elicit dilation in venules, but the mediation of response is not yet clarified. We hypothesized that – in addition to nitric oxide (NO) and dilator prostaglandins (PGI2/ PGE2) – thromboxane A2 (TxA2) contributes to the mediation of flow-induced responses of venules. Methods and Results: Isolated rat gracilis muscle venules (259 ± 11 μm at 10 mm Hg) dilated as a function of intraluminal flow, which was augmented in the presence of the TxA2 receptor antagonist SQ 29,548 or the TxA2 synthase inhibitor ozagrel. In the presence of SQ 29,548, indomethacin or Nω-nitro-L-arginine methyl-ester decreased flow-induced dilations, whereas in their simultaneous presence dilations were abolished. The selective cyclooxygenase (COX) 1 inhibitor SC 560 reduced, whereas the selective COX-2 inhibitor NS 398 enhanced flow-induced dilations. Immunohistochemistry showed that both COX-1 and COX-2 are present in the wall of venules. Conclusion: In skeletal muscle venules, increases in intraluminal flow elicit production of constrictor TxA2, in addition to the dilator NO and PGI2/PGE2, with an overall effect of limited dilation. These mediators are likely to have important roles in the multiple feedback regulation of wall shear stress in venules during changes in blood flow velocity and/or viscosity.

Keywords:
Venule, Shear stress, Nitric oxide, Prostaglandins, Cyclooxygenases 1 and 2, Thromboxane A2 synthase
1.
Hochauf S, Sternitzky R, Schellong SM: Structure and function of the peripheral venous system (in German). Herz 2007;32:3–9.
2.
Pang CC: Measurement of body venous tone. J Pharmacol Toxicol Methods 2000;44:341–360.
3.
Kuo L, Arko F, Chilian WM, Davis MJ: Coronary venular responses to flow and pressure. Circ Res 1993;72:607–615.
4.
Koller A, Dornyei G, Kaley G: Flow-induced responses in skeletal muscle venules: modulation by nitric oxide and prostaglandins. Am J Physiol 1998;275:H831–H836.
5.
Holtz J, Forstermann U, Pohl U, Giesler M, Bassenge E: Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: effects of cyclooxygenase inhibition. J Cardiovasc Pharmacol 1984;6:1161–1169.
6.
Bevan JA, Joyce EH: Saline infusion into lumen of resistance artery and small vein causes contraction. Am J Physiol 1990;259:H23–H28.
7.
Koller A, Mizuno R, Kaley G: Flow reduces the amplitude and increases the frequency of lymphatic vasomotion: role of endothelial prostanoids. Am J Physiol 1999;277:R1683–R1689.
8.
Dornyei G, Kaley G, Koller A: Release of nitric oxide and prostaglandin H2 to acetylcholine in skeletal muscle venules. Am J Physiol 1997;272:H2541–H2546.
9.
Koller A, Sun D, Huang A, Kaley G: Corelease of nitric oxide and prostaglandins mediates flow-dependent dilation of rat gracilis muscle arterioles. Am J Physiol 1994;267:H326–H332.
10.
Bagi Z, Erdei N, Toth A, Li W, Hintze TH, Koller A, Kaley G: Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 2005;25:1610–1616.
11.
Szerafin T, Erdei N, Fulop T, Pasztor ET, Edes I, Koller A, Bagi Z: Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res 2006;99:e12–e17.
12.
Nawa H, Kurosaki Y, Kawasaki H: Different prostanoids are involved in bradykinin-induced endothelium-dependent and -independent vasoconstriction in rat mesenteric resistance arteries. J Pharmacol Sci 2004;94:115–121.
13.
Koller A, Kaley G: Endothelium regulates skeletal muscle microcirculation by a blood flow velocity-sensing mechanism. Am J Physiol 1990;258:H916–H920.
14.
Koller A, Sun D, Kaley G: Role of shear stress and endothelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro. Circ Res 1993;72:1276–1284.
15.
Kuo L, Davis MJ, Chilian WM: Endothelium-dependent, flow-induced dilation of isolated coronary arterioles. Am J Physiol 1990;259:H1063–H1070.
16.
Davis MJ: Spontaneous contractions of isolated bat wing venules are inhibited by luminal flow. Am J Physiol 1993;264:H1174–H1186.
17.
Fukaya Y, Ohhashi T: Acetylcholine- and flow-induced production and release of nitric oxide in arterial and venous endothelial cells. Am J Physiol 1996;270:H99–H106.
18.
House SD, Johnson PC: Diameter and blood flow of skeletal muscle venules during local flow regulation. Am J Physiol 1986;250:H828–H837.
19.
Duling BR, Hogan RD, Langille BL, Lelkes P, Segal SS, Vatner SF, Weigelt H, Young MA: Vasomotor control: functional hyperemia and beyond. Fed Proc 1987;46:251–263.
20.
Green DJ, O’Driscoll G, Blanksby BA, Taylor RR: Control of skeletal muscle blood flow during dynamic exercise: contribution of endothelium-derived nitric oxide. Sports Med 1996;21:119–146.
21.
Friedman LS, Fitzpatrick TM, Bloom MF, Ramwell PW, Rose JC, Kot PA: Cardiovascular and pulmonary effects of thromboxane B2 in the dog. Circ Res 1979;44:748–751.
22.
Kadowitz PJ, Hyman AL: Comparative effects of thromboxane B2 on the canine and feline pulmonary vascular bed. J Pharmacol Exp Ther 1980;213:300–305.
23.
Koller A, Kaley G: Prostaglandins mediate arteriolar dilation to increased blood flow velocity in skeletal muscle microcirculation. Circ Res 1990;67:529–534.
24.
Frangos JA, Eskin SG, McIntire LV, Ives CL: Flow effects on prostacyclin production by cultured human endothelial cells. Science 1985;227:1477–1479.
25.
Bhagyalakshmi A, Frangos JA: Mechanism of shear-induced prostacyclin production in endothelial cells. Biochem Biophys Res Commun 1989;158:31–37.
26.
Myers TO, Messina EJ, Rodrigues AM, Gerritsen ME: Altered aortic and cremaster muscle prostaglandin synthesis in diabetic rats. Am J Physiol 1985;249:E374–E379.
27.
Gerritsen ME, Cheli CD: Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells. J Clin Invest 1983;72:1658–1671.
28.
Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, Wilson CB, Hwang D: Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993;307:361–368.
29.
Baber SR, Champion HC, Bivalacqua TJ, Hyman AL, Kadowitz PJ: Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation 2003;108:896–901.
30.
Baber SR, Deng W, Rodriguez J, Master RG, Bivalacqua TJ, Hyman AL, Kadowitz PJ: Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse. Am J Physiol Heart Circ Physiol 2005;289:H1476–H1487.
31.
McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272–277.
32.
Kawka DW, Ouellet M, Hetu PO, Singer II, Riendeau D: Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim Biophys Acta 2007;1771:45–54.
33.
Koller A, Kaley G: Endothelial regulation of wall shear stress and blood flow in skeletal muscle microcirculation. Am J Physiol 1991;260:H862–H868.
34.
Lipowsky HH, Kovalcheck S, Zweifach BW: The distribution of blood rheological parameters in the microvasculature of cat mesentery. Circ Res 1978;43:738–749.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.